Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Endevica Bio
Age
18–55
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Healthy males and females (WONCBP), aged 18 to 55 years inclusive, at time of signing informed consent.
Body mass index 18.0 to 30.0 kg/m2 as measured at Screening or, if outside this range, considered not clinically significant by the investigator.
Weight ≥ 50 kg at Screening
You may not be if
Serious adverse reaction or serious known hypersensitivity to melanocortins or polyethylene glycol.
Evidence of current severe acute respiratory syndrome coronavirus 2 infection.
Clinically significant abnormal clinical chemistry, hematology, or urinalysis as judged by the investigator.
Subjects who have received any IP in a clinical research study within 5 half-lives or within 30 days prior to first dose. However, in no event shall the time between last receipt of IP and first dose be less than 30 days.
